Bifogade filer
Kurs
-1,57%
Likviditet
183 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-11-25 | 07:30 | Kvartalsrapport 2027-Q2 |
| 2026-09-03 | N/A | Årsstämma |
| 2026-08-27 | 07:30 | Kvartalsrapport 2027-Q1 |
| 2026-05-28 | 07:30 | Bokslutskommuniké 2026 |
| 2026-03-05 | - | X-dag halvårsutdelning EKTA B 1.2 |
| 2026-03-05 | - | Kvartalsrapport 2026-Q3 |
| 2025-11-26 | - | Kvartalsrapport 2026-Q2 |
| 2025-09-05 | - | X-dag halvårsutdelning EKTA B 1.2 |
| 2025-09-04 | - | Årsstämma |
| 2025-08-28 | - | Kvartalsrapport 2026-Q1 |
| 2025-05-28 | - | Bokslutskommuniké 2025 |
| 2025-03-06 | - | X-dag halvårsutdelning EKTA B 1.2 |
| 2025-02-21 | - | Kvartalsrapport 2025-Q3 |
| 2024-11-27 | - | Kvartalsrapport 2025-Q2 |
| 2024-09-06 | - | X-dag halvårsutdelning EKTA B 1.2 |
| 2024-09-05 | - | Årsstämma |
| 2024-08-28 | - | Kvartalsrapport 2025-Q1 |
| 2024-06-05 | - | Bokslutskommuniké 2024 |
| 2024-02-29 | - | Kvartalsrapport 2024-Q3 |
| 2024-02-26 | - | X-dag halvårsutdelning EKTA B 1.2 |
| 2023-11-30 | - | Kvartalsrapport 2024-Q2 |
| 2023-08-25 | - | X-dag halvårsutdelning EKTA B 1.2 |
| 2023-08-24 | - | Årsstämma |
| 2023-08-24 | - | Kvartalsrapport 2024-Q1 |
| 2023-05-25 | - | Bokslutskommuniké 2023 |
| 2023-02-24 | - | X-dag halvårsutdelning EKTA B 1.2 |
| 2023-02-24 | - | Kvartalsrapport 2023-Q3 |
| 2022-11-24 | - | Kvartalsrapport 2023-Q2 |
| 2022-08-26 | - | X-dag halvårsutdelning EKTA B 1.2 |
| 2022-08-25 | - | Årsstämma |
| 2022-08-25 | - | Kvartalsrapport 2023-Q1 |
| 2022-05-25 | - | Bokslutskommuniké 2022 |
| 2022-02-24 | - | X-dag halvårsutdelning EKTA B 1.1 |
| 2022-02-24 | - | Kvartalsrapport 2022-Q3 |
| 2021-11-25 | - | Kvartalsrapport 2022-Q2 |
| 2021-08-26 | - | X-dag halvårsutdelning EKTA B 1.1 |
| 2021-08-25 | - | Årsstämma |
| 2021-08-25 | - | Kvartalsrapport 2022-Q1 |
| 2021-05-28 | - | Bokslutskommuniké 2021 |
| 2021-04-19 | - | X-dag bonusutdelning EKTA B 0.9 |
| 2021-04-16 | - | Extra Bolagsstämma 2021 |
| 2021-02-25 | - | Kvartalsrapport 2021-Q3 |
| 2020-11-26 | - | Kvartalsrapport 2021-Q2 |
| 2020-08-27 | - | X-dag halvårsutdelning EKTA B 0.9 |
| 2020-08-26 | - | Årsstämma |
| 2020-08-26 | - | Kvartalsrapport 2021-Q1 |
| 2020-05-29 | - | Bokslutskommuniké 2020 |
| 2020-02-21 | - | X-dag halvårsutdelning EKTA B 0.9 |
| 2020-02-20 | - | Kvartalsrapport 2020-Q3 |
| 2019-11-28 | - | Kvartalsrapport 2020-Q2 |
| 2019-08-23 | - | X-dag halvårsutdelning EKTA B 0.9 |
| 2019-08-22 | - | Årsstämma |
| 2019-08-22 | - | Kvartalsrapport 2020-Q1 |
| 2019-05-29 | - | Bokslutskommuniké 2019 |
| 2019-03-01 | - | X-dag halvårsutdelning EKTA B 0.7 |
| 2019-02-22 | - | Kvartalsrapport 2019-Q3 |
| 2018-11-29 | - | Kvartalsrapport 2019-Q2 |
| 2018-08-31 | - | X-dag halvårsutdelning EKTA B 0.7 |
| 2018-08-30 | - | Årsstämma |
| 2018-08-30 | - | Kvartalsrapport 2019-Q1 |
| 2018-06-01 | - | Bokslutskommuniké 2018 |
| 2018-03-02 | - | Kvartalsrapport 2018-Q3 |
| 2018-02-22 | - | X-dag halvårsutdelning EKTA B 0.5 |
| 2017-11-30 | - | Kvartalsrapport 2018-Q2 |
| 2017-08-24 | - | X-dag halvårsutdelning EKTA B 0.5 |
| 2017-08-23 | - | Årsstämma |
| 2017-08-23 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-01 | - | Bokslutskommuniké 2017 |
| 2017-03-03 | - | X-dag halvårsutdelning EKTA B 0.25 |
| 2017-03-01 | - | Kvartalsrapport 2017-Q3 |
| 2016-12-01 | - | Kvartalsrapport 2017-Q2 |
| 2016-09-26 | - | Kapitalmarknadsdag 2016 |
| 2016-09-02 | - | X-dag halvårsutdelning EKTA B 0.25 |
| 2016-09-01 | - | Årsstämma |
| 2016-09-01 | - | Kvartalsrapport 2017-Q1 |
| 2016-06-01 | - | Bokslutskommuniké 2016 |
| 2016-03-02 | - | Kvartalsrapport 2016-Q3 |
| 2015-12-03 | - | Kvartalsrapport 2016-Q2 |
| 2015-09-02 | - | X-dag ordinarie utdelning EKTA B 0.50 SEK |
| 2015-09-01 | - | Årsstämma |
| 2015-09-01 | - | Kvartalsrapport 2016-Q1 |
| 2015-06-02 | - | Bokslutskommuniké 2015 |
| 2015-03-04 | - | Kvartalsrapport 2015-Q3 |
| 2014-11-27 | - | Analytiker möte 2014 |
| 2014-11-27 | - | Kvartalsrapport 2015-Q2 |
| 2014-09-15 | - | Kapitalmarknadsdag 2014 |
| 2014-08-29 | - | X-dag ordinarie utdelning EKTA B 1.50 SEK |
| 2014-08-29 | - | X-dag bonusutdelning EKTA B 0.5 |
| 2014-08-28 | - | Analytiker möte 2015 |
| 2014-08-28 | - | Årsstämma |
| 2014-08-28 | - | Kvartalsrapport 2015-Q1 |
| 2014-05-28 | - | Analytiker möte 2014 |
| 2014-05-28 | - | Bokslutskommuniké 2014 |
| 2014-02-27 | - | Kvartalsrapport 2014-Q3 |
| 2013-12-04 | - | Kvartalsrapport 2014-Q2 |
| 2013-09-23 | - | Kapitalmarknadsdag 2013 |
| 2013-09-04 | - | X-dag ordinarie utdelning EKTA B 1.50 SEK |
| 2013-09-04 | - | X-dag bonusutdelning EKTA B 0.5 |
| 2013-09-03 | - | Årsstämma |
| 2013-09-03 | - | Kvartalsrapport 2014-Q1 |
| 2013-06-05 | - | Analytiker möte 2013 |
| 2013-06-05 | - | Bokslutskommuniké 2013 |
| 2013-03-05 | - | Extra Bolagsstämma 2013 |
| 2013-03-05 | - | Kvartalsrapport 2013-Q3 |
| 2012-12-04 | - | Kvartalsrapport 2013-Q2 |
| 2012-10-29 | - | Kapitalmarknadsdag 2012 |
| 2012-09-12 | - | Split EKTA B 1:4 |
| 2012-09-05 | - | X-dag ordinarie utdelning EKTA B 5.00 SEK |
| 2012-09-03 | - | Årsstämma |
| 2012-09-03 | - | Kvartalsrapport 2013-Q1 |
| 2012-06-05 | - | Analytiker möte 2012 |
| 2012-06-05 | - | Bokslutskommuniké 2012 |
| 2012-04-02 | - | Extra Bolagsstämma 2012 |
| 2012-03-05 | - | Kvartalsrapport 2012-Q3 |
| 2011-12-02 | - | Kvartalsrapport 2012-Q2 |
| 2011-09-14 | - | X-dag ordinarie utdelning EKTA B 4.00 SEK |
| 2011-09-13 | - | Årsstämma |
| 2011-09-13 | - | Kvartalsrapport 2012-Q1 |
| 2011-06-09 | - | Bokslutskommuniké 2011 |
| 2011-03-08 | - | Kvartalsrapport 2011-Q3 |
| 2010-12-07 | - | Kvartalsrapport 2011-Q2 |
| 2010-09-22 | - | X-dag ordinarie utdelning EKTA B 3.00 SEK |
| 2010-09-21 | - | Kvartalsrapport 2011-Q1 |
| 2010-06-09 | - | Bokslutskommuniké 2010 |
| 2010-03-10 | - | Kvartalsrapport 2009-Q3 |
| 2009-12-10 | - | Kvartalsrapport 2009-Q2 |
| 2009-09-16 | - | X-dag ordinarie utdelning EKTA B 2.00 SEK |
| 2009-09-15 | - | Årsstämma |
| 2009-09-15 | - | Kvartalsrapport 2009-Q1 |
| 2008-09-19 | - | X-dag ordinarie utdelning EKTA B 1.75 SEK |
| 2007-09-26 | - | X-dag ordinarie utdelning EKTA B 1.00 SEK |
| 2006-09-21 | - | X-dag ordinarie utdelning EKTA B 1.00 SEK |
| 2005-10-17 | - | Split EKTA B 1:3 |
| 2005-09-22 | - | X-dag ordinarie utdelning EKTA B 6.60 SEK |
| 2004-09-22 | - | X-dag ordinarie utdelning EKTA B 0.00 SEK |
| 2003-09-23 | - | X-dag ordinarie utdelning EKTA B 0.00 SEK |
| 2002-10-01 | - | X-dag ordinarie utdelning EKTA B 0.00 SEK |
| 2001-09-28 | - | X-dag ordinarie utdelning EKTA B 0.00 SEK |
| 2000-10-02 | - | X-dag ordinarie utdelning EKTA B 0.00 SEK |
| 1999-09-23 | - | X-dag ordinarie utdelning EKTA B 0.00 SEK |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Third quarter
- In constant exchange rates, net sales increased by 2 percent mainly driven by Europe and China. Reported sales in SEK decreased by 10 percent amounting to SEK 4,239 M (4,695).
- The book-to-bill ratio was 1.17 (1.15), supported by strong order intake in China, U.S. and Europe.
- Third quarter was impacted by a SEK 417 M restructuring charge related to change of the operating model, which is expected to reduce the cost base by more than SEK 500 M annually.
- Higher adjusted gross margin of 38.3 percent (37.1) driven by product launches and improved pricing.
- Tariff costs and changes in FX had a negative impact of 100 and 130 basis points respectively on the gross margin.
- Adjusted EBIT amounted to SEK 504 M (548), resulting in a margin of 11.9 percent (11.7). The positive effect from the gross margin was partly offset by higher amortization and a lower capitalization level.
- Net income was SEK 12 M (336) and basic earnings per share was SEK 0.03 (0.89).
- Cash flow after continuous investments declined to SEK 255 M (730) in Q3 partly due to severance payments and lower contribution from working capital, while YTD amounted to SEK 251 M (-192).
| Group summary | Q3 | First nine months | ||||||
| SEK M | 2025/26 | 2024/25 | Δ | 2025/26 | 2024/25 | Δ | ||
| Book-to-bill | 1.17 | 1.15 | 1% | 1.08 | 1.08 | -1% | ||
| Net sales | 4,239 | 4,695 | -10% | 11,955 | 12,860 | -7% | ||
| Net sales in constant exchange rates | 2% | 1 | 2% | 1 | ||||
| Adjusted gross margin 2 | 38.3% | 37.1% | 1.3 ppts | 37.8% | 36.8% | 1 ppts | ||
| Adjusted EBITDA 3 | 820 | 886 | -7% | 2,093 | 2,231 | -6% | ||
| Adjusted EBITDA margin 3 | 19.3% | 18.9% | 0.5 ppts | 17.5% | 17.3% | 0.2 ppts | ||
| Adjusted EBIT 4 | 504 | 548 | -8% | 1,150 | 1,254 | -8% | ||
| Adjusted EBIT margin 4 | 11.9% | 11.7% | 0.2 ppts | 9.6% | 9.8% | -0.1 ppts | ||
| Gross margin | 35.1% | 36.9% | -1.8 ppts | 36.5% | 36.5% | 0 ppts | ||
| EBITDA | 403 | 866 | -53% | 1,639 | 2,094 | -22% | ||
| EBITDA margin | 9.5% | 18.4% | -8.9 ppts | 13.7% | 16.3% | -2.6 ppts | ||
| EBIT | 87 | 525 | -83% | 696 | 1,087 | -36% | ||
| EBIT margin | 2.0% | 11.2% | -9.1 ppts | 5.8% | 8.5% | -2.6 ppts | ||
| Net income | 12 | 336 | -97% | 346 | 621 | -44% | ||
| Cash flow after continuous investments | 255 | 730 | -475 | 251 | -192 | 443 | ||
| Adjusted earnings per share before/after dilution, SEK 5 | 0.88 / 0.88 | 0.94 / 0.94 | -7% | 1.83 / 1.83 | 1.97 / 1.97 | -7% | ||
| Earnings per share before/after dilution, SEK | 0.03 / 0.03 | 0.89 / 0.89 | -97% | 0.91 / 0.91 | 1.63 / 1.63 | -44% | ||
1Compared to last fiscal year based on constant exchange rates.
2Adjusted gross margin = Gross margin excluding items affecting comparability, see page 28.
3Adjusted EBITDA = EBITDA excluding items affecting comparability, see page 28.
4Adjusted EBIT = Operating income (EBIT) excluding items affecting comparability, see page 29.
5Adjusted earnings per share = Net income excluding items affecting comparability, attributable to Parent Company shareholders, in relation to the weighted average number of shares (excluding treasury shares), see page 30.
A solid quarter with significant impact from currency and restructuring
Third quarter summary
Net sales in Q3, at constant exchange rates, increased by 2 percent year-over-year, driven by continued positive momentum in Europe, as well as China’s return to growth for the first time since Q3 2023/24. The book-to-bill ratio reached 1.17, supported by strong order intake in China and the U.S., as well as service orders in Europe.
The adjusted gross margin in Q3 improved year-over-year to 38.3 percent (37.1). The increase was mainly supported by product launches and improved pricing. The strengthening of the Swedish krona against major currencies and the depreciation of the U.S. dollar had an increasingly negative impact during the quarter, reducing gross margin by 130 basis points year-over-year. Adjusted EBIT margin for the third quarter ended at 11.9 percent (11.7) . The improvement was primarily driven by a higher gross margin and lower R&D spend while increased amortization and lower capitalization of R&D weighed negatively by 150 basis points in total year-over-year on the EBIT margin.
Year-to-date operating cash flow after continuous investments amounted to SEK 251 M, representing an improvement of SEK 443 M compared with last year despite severance payments related to the change of operating model.
Value creation through speed and continuous improvement
As previously communicated, Elekta has defined four priority areas, our Must-Win Battles, that will drive value creation through increased speed and continuous improvement. Through Must- Win Battle 1, we are implementing a new operating model aimed at simplifying and decentralizing the organization. As a result, we expect to achieve more than SEK 500 M in annualized cost savings, with the full effect realized in Q1 2026/27. The implementation of the new operating model is progressing well, with more than 80 percent of the planned workforce reductions already completed.
With Must-Win Battle 2, Focused Innovation, we aim to improve returns on R&D investment by sharpening our focus on projects that address commercial demand and shape the future of radiation therapy through our focus on adaptive treatments.
Winning in the U.S. and expanding in China are the priority areas included in Must-Win Battle 3. In the U.S., the launch of Evo and Elekta ONE have strengthened our product offering across hardware, software, and service with continued strong interest from customers. Expanding our presence in China represents the second pillar of this Must-Win Battle. To strengthen our competitiveness, we are further deepening the localization of Elekta’s portfolio and supply chain. We have maintained our market-leading position through a period of declining demand, and as the market begins to recover, we expect to see operating leverage from the Chinese business.
Must-Win Battle 4 focuses on reducing cost of goods sold and reinforcing our ambition to expand the gross margin, thereby freeing up resources for continued innovation. Key initiatives include introducing dual sourcing and cost efficient suppliers, deploying AI-tools to support field service engineers, improving order fulfillment efficiency, and simplifying installation and serviceability.
Outlook
We reiterate our full-year 2025/26 outlook, where we expect net sales in constant currency to grow year-over-year. Furthermore, we expect continuous negative impact on earnings from FX at current exchange rates and tariffs. On June 17, we will host a Capital Markets Day in Stockholm.
Jakob Just-Bomholt
President and CEO
This information is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-05 07:30 CET.